WYOM to Establish Joint Venture in China for Photodynamic Therapy Research with Shanghai Dusu

[Asia Economy Reporter Hyunseok Yoo] YOM announced on the 21st that it has held detailed discussions with Shanghai Dushu Biological Technology Service Co., Ltd. (hereinafter Shanghai Dushu) to promote the establishment of a joint venture for a Photodynamic Therapy (PDT) center in China.

YOM plans to accelerate the registration of active pharmaceutical ingredients and approval of medical devices for photodynamic therapy (PDT) through the joint venture PDT center. It will also proceed with clinical trial planning and selection of target cancer types in preparation for global clinical trials.

The photodynamic therapy (PDT) jointly researched by YOM and Shanghai Dushu is a next-generation anticancer treatment technology that selectively accumulates in cancer cells by directly injecting second-generation photosensitizers into cancer cells and then necrotizing the cancer cells with photodynamic lasers.

In October last year, YOM signed a memorandum of understanding (MOU) with Shanghai Dushu for research on pancreatic cancer treatment technology using second-generation photosensitizers in photodynamic therapy (PDT).

Jang Somun, CEO of Shanghai Dushu, said, "We plan to complete the establishment of the joint venture as soon as possible through close collaboration with YOM," adding, "The global clinical trials conducted by the joint venture will be promoted in the Shanghai area of China."

Byun Youngin, Vice President of YOM, stated, "With the stable supply of Photolon for global clinical trials from Belarus Belmedpreparaty (BPM), research on photodynamic therapy (PDT) is gaining momentum," and added, "We also plan to obtain patents for medical devices necessary for photodynamic therapy (PDT) soon."

This content was produced with the assistance of AI translation services.